Filtered By:
Condition: Bleeding
Drug: Plavix
Education: Study
This page shows you your search results in order of date.
Order by Relevance | Date
Total 485 results found since Jan 2013.
Ticagrelor versus clopidogrel after intracranial stent angioplasty: a real-world study
ConclusionIn our study involving patients with acute ischemic stroke who had undergone intracranial stenting, aspirin-ticagrelor was not found to be superior to aspirin-clopidogrel in reducing the rate of ischemic vascular events. The risk of bleeding did not differ between the two groups. Aspirin-ticagrelor does not lower total restenosis and symptomatic restenosis risk at follow-up.
Source: Frontiers in Neurology - August 11, 2023 Category: Neurology Source Type: research
Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials
CONCLUSIONS: Compared with aspirin monotherapy following short-term DAPT, ticagrelor following 3-month DAPT was associated with a reduced risk of primary bleeding outcomes without increasing any ischemic outcomes.PMID:37562542 | DOI:10.1016/j.jjcc.2023.08.001
Source: Journal of Cardiology - August 10, 2023 Category: Cardiology Authors: Satoshi Shoji Toshiki Kuno Hiroki Ueyama Hisato Takagi Alexandros Briasoulis Hyo-Soo Kim Bon-Kwon Koo Jeehoon Kang Hirotoshi Watanabe Takeshi Kimura Shun Kohsaka Source Type: research
Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network Meta-analysis of randomized trials
CONCLUSIONS: Compared with aspirin monotherapy following short-term DAPT, ticagrelor following 3-month DAPT was associated with a reduced risk of primary bleeding outcomes without increasing any ischemic outcomes.PMID:37562542 | DOI:10.1016/j.jjcc.2023.08.001
Source: Journal of Cardiology - August 10, 2023 Category: Cardiology Authors: Satoshi Shoji Toshiki Kuno Hiroki Ueyama Hisato Takagi Alexandros Briasoulis Hyo-Soo Kim Bon-Kwon Koo Jeehoon Kang Hirotoshi Watanabe Takeshi Kimura Shun Kohsaka Source Type: research
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial
CONCLUSIONS: In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04078737.PMID:37548009 | DOI:10.1161/STROKEAHA.122.042233
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Xuewei Xie Jing Jing Xia Meng S Claiborne Johnston Philip M Bath Zixiao Li Xingquan Zhao Liping Liu Yilong Wang Qin Xu Anxin Wang Yong Jiang Hao Li Yongjun Wang CHANCE-2 Investigators Source Type: research
Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study
Conclusion: In real practice, ticagrelor swi tching among patients with STE-ACS post streptokinase therapy did not differ regarding safety outcomes and composite of efficacy outcomes compared with clopidogrel.
Source: PLoS One - August 4, 2023 Category: Biomedical Science Authors: Phornpaka Ueapornpanith Source Type: research
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis
ConclusionsWhen compared with clopidogrel, even though ticagrelor was not associated with higher risk of adverse cardiovascular outcomes in these patients with CKD, it was associated with significantly higher BARC bleeding. Therefore, the safety outcomes of ticagrelor still require further evaluation in patients with CKD. Nevertheless, this hypothesis should only be confirmed with more powerful results that could usually only be achieved using large-scale randomized trials.
Source: American Journal of Cardiovascular Drugs - August 2, 2023 Category: Cardiology Source Type: research
O-042 Complications of DAPT cessation at 3 months versus 6 months after flow diversion of unruptured intracranial aneurysms
ConclusionsOnly 0.6% (n=1) of patients exhibited complications after 3 month follow-up. We conclude that DAPT duration of 3 months after endoluminal flow diversion of unruptured cerebral aneurysms of the anterior circulation is not associated with increased rates of hemorrhagic or thromboembolic complications compared to a traditional 6-month regimen.Disclosures S. Srinivasan: None. A. White: None. M. Al-Abdulkareem: None. J. Barr: None. L. Pride: None. J. White: None. R. Novakovic-White: None. R. Sillero: None. B. Welch: None.
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Srinivasan, S., White, A., Al-Abdulkareem, M., Barr, J., Pride, L., White, J., Novakovic-White, R., Sillero, R., Welch, B. Tags: SNIS 20th annual meeting oral abstracts Source Type: research
Acute coronary syndrome in very elderly patients —a real-world experience
AbstractVery elderly population constitutes an increasingly larger proportion of patients admitted for acute coronary syndromes (ACS). Notably, age represents both a proxy of frailty and an exclusion criterion in clinical randomized trials, which probably contributes to lack of data and undertreatment of real-world elderly patients. The aim of the study is to describe patterns of treatment and outcome of very elderly patients with ACS. All consecutive patients aged ≥ 80 years old (yo) admitted between January 2017 and December 2019 with ACS were included. The primary endpoint was in-hospital occurrence of major adv...
Source: Heart and Vessels - July 15, 2023 Category: Cardiology Source Type: research
The contribution of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study
ConclusionsGenotype-guided selection of P2Y12 inhibitor made a very positive contribution on the prognosis in Chinese ACS/CCS patients undergoing PCI. Instead of intensifying antiplatelet strategies, conventional-dose clopidogrel could be recommended as P2Y12 inhibitor after weighing MACEs and bleeding events in CYP2C19 IM patients.
Source: European Journal of Clinical Pharmacology - July 14, 2023 Category: Drugs & Pharmacology Source Type: research
Multicenter Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor for Neuroendovascular Stents
ConclusionsUsing DAPT-C or DAPT-T regimens in a broad population of neuroendovascular stenting procedures appears to have similar safety and efficacy profiles. Further prospective evaluation is warranted to streamline the practice of DAPT selection and monitoring to determine the impact on clinical outcomes.
Source: Neurocritical Care - June 15, 2023 Category: Neurology Source Type: research
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke
ConclusionsThis real-world study suggests that cilostazol is effective and safe for noncardioembolic ischemic stroke and may be associated with better effectiveness in hypertensive patients compared to clopidogrel.
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research
Dual Versus Mono Antiplatelet Therapy in Patients with Acute Mild-to-Moderate Stroke: A Multicentre Perspective Cohort Study
ConclusionAspirin plus clopidogrel was associated with a reduction in the incidence of disability attributed to index stroke. There was no statistically significant difference in the incidence of moderate to severe bleeding complications between the two antiplatelet drug regimens.Trial Registration NumberChiCTR1900025214.
Source: Cardiovascular Drugs and Therapy - June 13, 2023 Category: Cardiology Source Type: research
